Laboratorios Farmaceuticos ROVI (ROVI.MC) Hisse Fiyat
Laboratorios Farmaceuticos ROVI Fiyat
Gelir, son 19 yılda yıllık bileşik %12,6 artarak 743,48 M EUR seviyesine ulaştı. Hisse başına kâr, son 19 yılda yıllık %19,0 büyüdü. Laboratorios Farmaceuticos ROVI şirketinde net marj %18,9 seviyesinde bulunuyor; birkaç yıl önceki %23,6 seviyesine göre geriledi. Laboratorios Farmaceuticos ROVI şu anda yaklaşık %1,59 temettü verimi sunuyor. Temettü dağıtım oranı, kârın yaklaşık %34 düzeyindedir. Temettü, son 17 yılda yıllık %15,7 artış gösterdi. Analistler 85,07 EUR medyan fiyat hedefi belirliyor; bu, güncel fiyatın %44,4 üzerinde bir seviyeye işaret ediyor. 16 analistten 13 tanesi hisse için alım öneriyor — genel konsensüs: Al.
Laboratorios Farmaceuticos ROVI hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
Laboratorios Farmaceuticos ROVI iş modeli ve hisse analizi
Laboratorios Farmaceuticos ROVI hakkında sık sorulan sorular
The business model of Laboratorios Farmaceuticos ROVI SA focuses on pharmaceutical research, development, manufacturing, and commercialization. The company operates in the specialty pharmaceuticals industry and specializes in the production of injectable pharmaceuticals and various other drugs. Laboratorios Farmaceuticos ROVI SA collaborates with international partners for the licensing and distribution of its products. With a strong emphasis on innovation and quality, the company aims to provide healthcare solutions through its unique product portfolio. Laboratorios Farmaceuticos ROVI SA actively pursues partnerships and collaborations to expand its market reach and continuously improve its product pipeline.
Laboratorios Farmaceuticos ROVI SA is primarily active in the pharmaceutical industry.
The main competitors of Laboratorios Farmaceuticos ROVI SA in the market include pharmaceutical companies such as Novartis, Pfizer, Johnson & Johnson, and Sanofi.
Laboratorios Farmaceuticos ROVI SA is a renowned pharmaceutical company with an impressive history and background. Established in 1946, ROVI SA has consistently focused on developing and manufacturing innovative healthcare solutions. With its headquarters in Madrid, Spain, the company operates in various therapeutic areas, including Special Focused Medicines, Biosimilars, and Active Pharmaceutical Ingredients (APIs). ROVI SA has a strong commitment to research and development, striving to improve patients' quality of life through cutting-edge treatments. Over the years, the company has gained recognition and trust from healthcare practitioners and patients alike, solidifying its position as a prominent player in the pharmaceutical industry.
Laboratorios Farmaceuticos ROVI SA has achieved several significant milestones throughout its history. One noteworthy achievement is its development of innovative pharmaceutical products, including advanced drug delivery systems and therapeutic solutions. The company has also gained recognition for its expertise in biopharmaceutical manufacturing and has successfully established numerous strategic partnerships globally. Additionally, Laboratorios Farmaceuticos ROVI SA has demonstrated consistent growth and profitability, expanding its market presence and enhancing shareholder value. These achievements reflect the company's commitment to delivering high-quality healthcare solutions and driving advancements within the pharmaceutical industry.
Laboratorios Farmaceuticos ROVI SA is primarily present in Spain, where the company is based. Additionally, ROVI has a global presence, with its products and services being available in several other countries and regions around the world. These include various European countries such as Germany, France, Italy, Portugal, and the United Kingdom. Furthermore, ROVI has a significant presence in the Americas, including Mexico, Brazil, and Colombia. With its international reach, Laboratorios Farmaceuticos ROVI SA has established a strong presence in both European and American markets, catering to a wide range of customers and expanding its global footprint.
Laboratorios Farmaceuticos ROVI SA represents values of innovation, integrity, and excellence in the pharmaceutical industry. With a strong corporate philosophy centered on the development and manufacturing of innovative medicines and healthcare products, ROVI prioritizes patient well-being and strives for scientific advancement. The company's commitment to research and development, along with its focus on partnerships with healthcare professionals and organizations, enables ROVI to provide innovative solutions that improve patients' lives. By embracing a culture of responsibility, transparency, and ethical practices, Laboratorios Farmaceuticos ROVI SA aims to contribute to global healthcare and deliver value to its stakeholders.
Analistler şu anda Laboratorios Farmaceuticos ROVI hissesi için ortalama 84,26 EUR hedef fiyat belirliyor (medyan: 85,07 EUR); bu, son fiyata göre +43,5 % anlamına gelir. Konsensüs 16 analist notuna dayanır.
Laboratorios Farmaceuticos ROVI Analist Fiyat Hedefleri 2026
16 analist şu anda Laboratorios Farmaceuticos ROVI hissesini değerlendiriyor: 13 al, 3 tut, 0 sat öneriyor. 2026 için analistler Laboratorios Farmaceuticos ROVI şirketinin 774,25 M EUR gelir ve 2,79 EUR hisse başına kâr üretmesini bekliyor.
Laboratorios Farmaceuticos ROVI Analist Fiyat Hedefleri 2026
Laboratorios Farmaceuticos ROVI hissesi (ROVI.MC) 9 borsada işlem görür, bunlar arasında: London (0ILL.L), SIX (Zürich) (41L.SW), Frankfurt (41L.F), München (41L.MU), Düsseldorf (41L.DU), Madrid (ROVI.MC).
Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the development and production of biotechnological drugs, vaccines, and generics. The company was founded in Spain in 1946 and has since built an impressive track record. Today, ROVI is a global player with customers in over 80 countries worldwide. ROVI operates in three business segments: Innovation, Generics, and Specialties. In the Innovation segment, the company focuses on biotechnological drugs and vaccines, with a particular emphasis on tissue repair, kidney and liver diseases, and immuno-oncology. The pipeline of Innovation includes a variety of innovative drugs in various stages of clinical development. A significant milestone for the company was the successful approval of Doria®, an inactivated SARS-CoV-2 vaccine for individuals aged 18 years and older. In the Generics segment, ROVI focuses on high-quality generics for various diseases. The company has strong partnerships worldwide, giving it access to a broad network of producers and suppliers. ROVI is an important supplier to the public health sector in many countries. The Specialties segment comprises different products, such as contrast agents for medical imaging, wound care, and non-surgical wrinkle treatment. ROVI's product range includes a variety of drugs and vaccines for different diseases and applications. Some of the most well-known products are Envarsus® for preventing transplant rejection in kidney or liver transplantations, Bemiparin as an anticoagulant for the prevention and treatment of thrombosis, and Hepacare® for the treatment of Hepatitis C, used in countries like Pakistan to reduce the spread of the disease. To meet the growing needs of the healthcare market, ROVI has invested in research and development. The company has expanded its research and development pipeline and works on developing innovative drugs and products. ROVI is also known for investing in partnerships. The company collaborates closely with other bio-pharmaceutical companies and research institutes to develop new drugs. These partnerships also open up new markets and provide access to new technologies. In summary, ROVI SA has been active as a strategic and influential company in the biopharmaceutical world. Investments in research and development, innovation, and partnerships have contributed to ROVI's recognition in the industry. With a wide network of producers and suppliers worldwide and customers in over 80 countries, ROVI is globally present and has established a strong position in the public health sector.
beklenen'nin Laboratorios Farmaceuticos ROVI hasılatı 774,25 M EUR'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Laboratorios Farmaceuticos ROVI karı 142,61 M EUR'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Laboratorios Farmaceuticos ROVI'nin Fiyat/Kazanç (F/K) oranı şu anda 21,12'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Laboratorios Farmaceuticos ROVI hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Laboratorios Farmaceuticos ROVI'nin Fiyat/Satış (F/S) oranı şu anda 3,89'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Laboratorios Farmaceuticos ROVI hisse senedinin değerleme metriği olarak hizmet eder.
Laboratorios Farmaceuticos ROVI'nin Eulerpool Kalite Puanı 6/10'dur.
Laboratorios Farmaceuticos ROVI'nin ISIN'i ES0157261019'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Laboratorios Farmaceuticos ROVI'nin WKN'i A0M0GQ'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Laboratorios Farmaceuticos ROVI'nin ticker'ı ROVI.MC'dir. Ticker sembolü, Laboratorios Farmaceuticos ROVI hisseleri borsada işlem görmek için kullanılır.
Laboratorios Farmaceuticos ROVI Hissesi
Laboratorios Farmaceuticos ROVI Emsaller Grubu
Laboratorios Farmaceuticos ROVI Ticker
Laboratorios Farmaceuticos ROVI FIGI
Laboratorios Farmaceuticos ROVI'nin tüm temel göstergeleri ve derinlemesine analizi
Laboratorios Farmaceuticos ROVI hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Laboratorios Farmaceuticos ROVI şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: